Adverse effects of androgen-deprivation therapy in prostate cancer and their management
Rhee, Handoo, Gunter, Jennifer H., Heathcote, Peter, Ho, Ken, Stricker, Phillip, Corcoran, Niall M., & Nelson, Colleen C. (2015) Adverse effects of androgen-deprivation therapy in prostate cancer and their management. BJU International, 115(S5), pp. 3-13.
To provide an up-to-date summary of current literature on the management of adverse effects of androgen-deprivation therapy (ADT).
Patients and Methods
All relevant medical literature on men with prostate cancer treated with ADT from 2005 to 2014, and older relevant papers, were reviewed. Recent health advisory statements from the Australian government, societies and advocacy groups have been incorporated to the document.
There are numerous adverse effects of ADT that require pro-active prevention and treatment. Ranging from cardiovascular disease, diabetes and osteoporosis, to depression, cognitive decline and sexual dysfunction, the range of adverse effects is wide. Baseline assessment, monitoring, prevention and consultation from a multidisciplinary team are important in minimising the harm from ADT.
This review provides a series of practical recommendations to assist with managing the adverse effects of ADT.
Impact and interest:
Citation counts are sourced monthly from and citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from theindexing service can be viewed at the linked Google Scholar™ search.
|Item Type:||Journal Article|
|Additional Information:||Special Issue: Urological Society of Australia and New Zealand. The Urological Society of Australia and New Zealand and Wiley have published this supplement with no financial support|
|Keywords:||androgen-deprivation therapy, prostate cancer, adverse effects|
|Subjects:||Australian and New Zealand Standard Research Classification > MEDICAL AND HEALTH SCIENCES (110000) > ONCOLOGY AND CARCINOGENESIS (111200) > Cancer Cell Biology (111201)
Australian and New Zealand Standard Research Classification > MEDICAL AND HEALTH SCIENCES (110000) > ONCOLOGY AND CARCINOGENESIS (111200) > Cancer Therapy (excl. Chemotherapy and Radiation Therapy) (111204)
|Divisions:||Current > Schools > School of Biomedical Sciences
Current > QUT Faculties and Divisions > Faculty of Health
Current > Institutes > Institute of Health and Biomedical Innovation
|Copyright Owner:||© 2014 The Authors. BJU International © 2014 BJU International|
|Deposited On:||29 Oct 2015 01:50|
|Last Modified:||12 Sep 2016 23:40|
Repository Staff Only: item control page